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In 2015, the World Health Organization (WHO) declared tuberculosis (TB) to be responsible for more deaths than
any other single infectious disease. The burden of TB among children has frequently been dismissed as relatively
low with resulting deaths contributing very little to global under-five all-cause mortality, although without rigorous
estimates of these statistics the burden of childhood TB was, in reality, unknown. Recent work in the area has
resulted in a WHO estimate of 1 million new cases of childhood TB in 2014 resulting in 136,000 deaths. Around
3% of these cases likely have multidrug-resistant TB and at least 40,000 are in HIV-infected children. TB is now
thought to be a major or contributory cause of many deaths in children under five years old, despite not being
recorded as such, and is likely in the top ten causes of global mortality in this age group. In particular, recent
work has shown that TB is an underlying cause of a substantial proportion of pneumonia deaths in TB-endemic
countries. Childhood TB should be given higher priority: we need to identify children at greatest risk of TB disease
and death and make more use of tools such as active case-finding and preventive therapy. TB is a preventable and
treatable disease from which no child should die.
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In 1963, Edith Lincoln and Edward Sewell wrote in their
seminal book ‘Tuberculosis in Children’: “At the present
time the death rate from tuberculosis is markedly re-
duced in some areas and it is possible to look forward to
the day when tuberculosis will no longer be a public
health problem [1].” More than 50 years later, in 2015,
the World Health Organization (WHO) declared tuber-
culosis (TB) to be the number one killer among infec-
tious diseases [2].
The underlying reasons for this resurgence are com-
plex. They include HIV, the oldest known sample of
which was taken just three years before the publication
of ‘Tuberculosis in Children’, although it was not identi-
fied as HIV until many decades later [3]. Another con-
tributory factor, drug resistance, was already known
about in 1963, although few could have foretold the
devastating impact it would have on TB control. But
what has the impact been on children? What proportion
of the estimated 9.6 million new TB cases in 2015 [2]
occurred in children? How many were HIV-infected or
infected with drug-resistant TB? And how many died?Correspondence: jenkins.helen@gmail.com
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largely because the diagnosis of TB in children still
relies heavily on the methods that Edith Lincoln was
using in Bellevue Hospital more than half a century
ago [1]. However, there is a growing understanding
that many cases of TB disease in children are not
reported as such [4].
While TB is the number one infectious cause of
death among all age groups, pneumonia bears that
title among children under five years old, with an es-
timated 935,000 deaths in 2013 [5]. Mycobacterium
tuberculosis, the causative agent of tuberculosis, is
also a recognized, although under-diagnosed, cause of
pneumonia, especially in TB-endemic areas and
among HIV-infected children [6]. A recent review
found that between 1% and 23% of pneumonia cases
also had TB disease [7]. The true extent to which tu-
berculosis is an underlying cause of morbidity and
mortality attributed to other causes is unknown,
largely due to problems with the diagnosis of TB in
children [4]. However, with increasing attention on
childhood TB in recent years [8], there have been
considerable steps taken to use mathematical and
statistical tools to help us understand the true burden
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burden of childhood TB, with specific reference to inci-
dence and mortality, as well as the impact of HIV and
drug resistance on this vulnerable and often neglected
population.
Why is it important to understand the burden of
childhood TB?
Firstly, we must consider what we mean by the word
“burden”. Burden is a non-specific term measuring the
impact of a health problem in terms of financial cost,
mortality, morbidity or other indicators and here we will
focus primarily on morbidity and mortality due to vary-
ing forms of TB. The reasons behind the need to under-
stand disease burdens are broadly similar across
diseases: without robust estimates of the true burden of
disease, we cannot identify gaps in identification of
cases, estimate the resources required to reduce this
burden, begin to plan the types of interventions that
might be effective or measure the impact of these inter-
ventions. The specific reasons for understanding the
burden of childhood TB have been covered previously
[9] but include the need to raise advocacy for childhood
TB, which has been traditionally much neglected [10]; a
need for increased research into improved diagnostics
and treatment regimens specifically for children; demon-
stration of the importance of TB in the context of over-
all childhood morbidity and mortality; and also because
childhood TB is a surveillance indicator for recent trans-
mission within a community [11].
The END TB Strategy from WHO has the specific
aims of reducing global TB incidence and mortality by
90% and 95% respectively by the year 2035 [12]. How-
ever, without good estimates of incidence and mortality
it will be impossible to know if these targets have beenTable 1 Annual estimates of the childhood tuberculosis (TB) burden
Measure TB disease Fraction o
TB incidence 999,792 (95% CI: 937,877 – 1,055,414)a
847,000 (IQR: 558,000 – 1,280,000)b N/A
1,000,000 (UI: 900,000–1,100,000)c
150,000d
INH-R TB 120,872 (95% CI: 96,628–149,059)c 12.1% (95
84,000be 9.9%b
MDR-TB 31,948 (95% CI: 25,594–38,663)a 3.2%a
24,800 (IQR: 16,100–37,400)b 2.9% (IQR:
Mortality 136,000 (range: 115,000–157,000)c 13.6%c
60,000d
INH-R Isoniazid resistant, MDR Multidrug-resistant, CI Confidence Interval, IQR Interq
aJenkins et al. 2014 [17]; bDodd et al. 2016 [21]; cWHO 2015 [2]; dMurray et al. 2014
Yuen et al. 2015 [35]
eNote that Dodd et al. 2016 produced an estimate of INH-R TB mono-resistance of
all forms of INH-R (i.e. mono-resistance plus MDR-TB) but because this was not formmet. Children make up 26% of the global population and
43% of the population in low-income countries [13].
Therefore, to monitor our progress towards the END TB
goals, we need robust estimates of incidence and mortal-
ity in children.
Incidence of childhood TB disease
In 2011, the WHO produced their first estimate of glo-
bal childhood (<15 years) TB annual incidence of
490,000 [14], assuming equal case detection rates in chil-
dren and adults. Earlier estimates had included 663,990
[15] (1990), 884,019 [16] (2000) and 1,039,000 [15]
(2000). In 2014, three new pediatric TB incidence
estimates were put forward. Jenkins et al. published an
estimate of approximately 1 million [17] (Table 1). This
was produced by scaling up age-disaggregated smear
positive notifications reported to the WHO, in such a
way as to account for the substantial difference that
exists between adults and children in terms of the pro-
portion of all TB cases expected to be smear positive
[18, 19]. In the second method, Dodd et al. used a math-
ematical model that estimated the incidence of TB infec-
tion in children using WHO TB prevalence data and
demographic information [20]. Their model then esti-
mated childhood TB disease incidence by incorporating
the age-dependent risk of progression from infection to
disease, accounting for HIV infection and Bacille
Calmette-Guerin vaccination. They estimated that there
were 651,000 incidence cases of childhood TB in the 22
high-burden countries (HBCs) [20] in 2010. This was
later updated to produce a global estimate of around
850,000 [21] in 2014 (Table 1). A third independent
group, the Institute of Health Metrics and Evaluation
(IHME), estimated that there were 150,000 incident
pediatric TB cases in 2013 [22] (among HIV-negativeamong children aged 0-14 years
f all pediatric TB cases Latent TB infection
67 million (IQR: 52.3 million – 85.7 million)b
% CI: 9.8%–14.8%)c
6.8 millionb
2.7%–3.1%)b 2.0 million (IQR: 1.6 million–2.6 million)b
N/A
uartile range, UI Uncertainty Interval
(Note: there are no uncertainty ranges around these estimates);
58,300 (IQR: 38,300 – 87,000) cases. The figure presented of 84,000 represents
ally estimated in Dodd et al. 2016, there is no IQR around this result
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cases notified by countries to the WHO.
Following a meeting of the WHO Global Task Force
on TB Impact Measurement in 2015 [23], it was recom-
mended that the WHO combine the methods of Jenkins
et al. [17] and Dodd et al. [20] to produce their pediatric
TB incidence estimates [23]. The method of Murray
et al. was excluded due to lack of information about the
uncertainty of the estimate [24]. The new WHO com-
bined estimate was 1 million incident child TB cases in
2014 [2] (Table 1).
Given that only 359,000 pediatric TB cases were
notified to the WHO in 2014, this implies that two-
thirds of all children that developed active TB disease
in 2014 were not notified. The assumption is that
these children were not diagnosed and therefore did
not receive treatment. The morbidity and mortality
implications of so many children not receiving treat-
ment are profound and very worrying. Estimation of
how many of these “invisible” children exist has been
an essential part of raising advocacy for these
children and demonstrating the need for improved
diagnostics [25] and methods to find these children
(e.g. active case-finding [26]). TB is both preventable
and treatable but we need to identify these children
in the first place.
Of particular concern are children under the age of
five years. These children are less likely to be diagnosed
with TB, given that they have the disease, but more likely
to suffer serious sequelae such as TB meningitis [27]. So
far, Dodd et al. are the only group to specifically estimate
TB incidence in children under five, although WHO
under-five estimates may be published in their annual
TB report later in 2016. Dodd et al. estimated that 51.4%
of all pediatric cases of TB disease in 2014 occurred in
children under five years of age [21] (Table 2). Applying
this to the WHO pediatric TB incidence estimate would
indicate that 514,000 children under five years of age de-
veloped TB disease in 2014, which is nearly four and half
times the number notified to the WHO for that year
[28].Table 2 Annual estimated burden of childhood tuberculosis
(TB) among children aged 0–4 yearsa
Measure Estimate (Interquartile
range)
Fraction of all pediatric
TB (0–14 years of age)
TB incidence 435,000 (278,000–
651,000)
51.4%
Isoniazid-resistant TB 42,200b 50.2%
Multidrug-resistant TB 12,700 (8,020–19,000) 51.2%
aAll estimates are from Dodd et al. 2016 [21]
bNote that Dodd et al. 2016 produced an estimate of INH-R TB mono-resistance
of 29,500 (IQR: 18,800 - 44,300) cases. The figure presented of 42,200 represents
all forms of INH-R (i.e. mono-resistance plus MDR-TB) but because this was not
formally estimated in Dodd et al. 2016, there is no IQR around this resultDrug-resistant TB disease
Drug-resistant TB is under-diagnosed among all age
groups due to the resources and costs required for diag-
nosis and limited access to testing facilities in many
parts of the world [29]. Difficulties with obtaining
bacteriologically positive sputum from children with
TB only serve to amplify these issues [30]. It is be-
lieved that the majority of cases of pediatric drug-
resistant TB are undiagnosed as such and therefore
inappropriately treated [11], if they receive any treat-
ment at all. With so much under-diagnosis of
pediatric drug-resistant TB, how do we know how
many children globally develop active TB disease
annually due to a drug-resistant strain?
Until 2014, no estimate of the global burden of
multidrug-resistant (strains resistant to the drugs isonia-
zid and rifampicin, the backbone of TB therapy) TB
(MDR-TB) existed. A systematic review of the literature
published before 12 January 2012 identified 97 reports
that included 8,382 children with drug-susceptibility re-
sults for isoniazid and rifampicin [17]. Of these, 348
children tested positive for MDR-TB. In 2012, authors
from the WHO reported results from an analysis of their
full database of the Global Project on Anti-tuberculosis
Drug Resistance Surveillance [31] on MDR-TB reporting
between 1994 and 2011. They found that of 6,070
children tested for MDR-TB, 456 were positive. A 2012
review of the literature published before 31 October
2011 on treatment outcomes among children with
MDR-TB identified 315 children with MDR-TB [32].
These three studies taken together indicate that, even
assuming no overlapping of study populations, just 1,119
children with MDR-TB have been documented in the
published literature.
In 2014, the first global estimate of the annual inci-
dence of pediatric MDR-TB was published [17]. This
work reviewed the literature for studies that included
both children and adults tested for MDR-TB in the same
setting and quantified the relationship between the per-
centage of new (treatment-naïve) adult TB cases with
MDR-TB and the percentage observed in children. The
authors then used WHO national estimates of the
percentage of new TB cases with MDR-TB by country
to estimate the percentage of childhood TB cases that
had MDR-TB for every country worldwide. They then
multiplied these percentages by their aforementioned
pediatric TB estimates to obtain the global estimated
number of pediatric MDR-TB cases in 2010 of 32,000
[17] (Table 1), i.e. 3.2% of total childhood TB
incidence.
Although outcomes for children with MDR-TB who
receive appropriate treatment can be excellent [32, 33],
the vast majority of these 32,000 annual new cases are
never correctly diagnosed with MDR-TB, much less
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the 1,119 children ever reported in the literature repre-
sent just 3.5% of the total incident cases that occur in
one year.
The burden of other forms of drug-resistant TB also
requires quantification. Isoniazid preventive therapy
(IPT) is one of our most effective, but under-used, tools
against pediatric TB [34]. However, its effectiveness
could be undermined by isoniazid-resistant (INH-R)
latent TB infection (LTBI). A recent review by Yuen
et al. estimated that 12.1% of children with TB globally
had INH-R TB disease (including mono-resistance and
combined with other forms of resistance), representing
121,000 cases of disease [35] (Table 1). This percentage
was highest in the former Soviet Union countries.
Assuming that the percentage of TB cases with isoniazid
resistance in children with active disease is reflected in
those with LTBI, isoniazid preventive therapy will be
ineffective in 12.1% of children with TB. It therefore cru-
cial to understand which children might be at highest
risk of INHR-TB so that other preventive methods can
be used, such a regimen containing rifapentine or rifam-
picin [36].
Finally, Dodd et al. recently published an extension of
their mathematical model to estimate the number of
children with several different forms of drug-resistant
TB [21]. Noting that their estimates worked from a
lower baseline of overall TB incidence than those of
Jenkins et al., they estimated that 24,800 had MDR-TB
(i.e. 2.9% of all TB incidence) (Table 1) and 58,300 had
mono-INH-R TB (i.e. 6.9% of all TB incidence). For
comparison with the results from Yuen et al., the total
INH-R TB resistance estimate from Dodd et al. was
84,000 cases constituting approximately 9.9% of all
pediatric TB cases [21]. In addition, they estimated that
1,160 children had extensively drug-resistant TB (TB
that is MDR-TB plus resistance to a fluoroquinolone
and an injectable drug).
TB incidence among HIV-infected children
Despite the known importance of HIV co-infection in
TB infected and diseased individuals [37], there are
no estimates of the global burden of TB specifically
in HIV-infected children. Dodd et al. estimated that
5.0% (IQR: 2.4%, 10.1%) of TB incidence in the 22
HBCs occurs in HIV-infected children [20]. This
translates to 32,500 HIV-infected children developing
active TB disease in the HBCs in 2010. A back-of-
the-envelope calculation would suggest that globally
in 2014 between 40,000 and 50,000 HIV-infected
children developed TB disease.
We currently have two effective ways to prevent TB
disease in TB-infected children: isoniazid prophylaxis
[38] and anti-retroviral treatment (Dodd et al. inpreparation). Many of these 40,000–50,000 annual cases
could be prevented with more rigorous deployment of
these preventive measures.
Childhood mortality due to TB
Globally, an estimated 6.3 million children under five
years old died in 2013 [5] from all causes. But how many
of these children are dying from TB? The first WHO
estimates of TB mortality among children, released in
2015, found that 136,000 children under fifteen years old
died in 2014 from TB [2] (Table 1). This estimate was
based on data from vital registration systems and mortal-
ity surveys from 129 countries; an imputation method was
used for the remaining countries without such data
(largely from Africa). Vital registration death data have
several limitations. For example, a cause might not be
attributed [39] or if it is, it might be incorrect, especially if
only one cause of death is allowed [40], despite multiple
contributory causes. For example, studies have shown that
TB may come close to bacterial pneumonia as a respira-
tory cause of death in children [41, 42]. In addition, in
many countries there are few resources to carry out aut-
opsies, and some deaths may not even be registered at all
[43]. These limitations are likely to be amplified in high
TB burden countries with few resources to carry out
detailed autopsies. The IHME group also produced child-
hood TB mortality estimates of 60,000 TB-related deaths
among HIV-negative children in 2014 [22].
An alternative method of estimating the number of
children dying with TB is to multiply case fatality ratios
(CFR; which could be defined in this context as the per-
centage of children that die within a year of a TB diag-
nosis) by the estimated incidence of pediatric TB. A
recent systematic review and meta analysis has quanti-
fied CFRs among children with TB [44]. In particular,
the authors searched the pre-chemotherapy literature to
understand CFRs in children that do not receive TB
treatment. The authors estimated that 21.9% (95% CI:
18.1%, 26.4%) of children from the pre-chemotherapy
era studies died from TB, within a year of TB diagnosis.
The case fatality ratio among children aged under 5 years
old was substantially worse at 43.6% (95% CI: 36.8%,
50.6%) [44]. Children receiving treatment faired consid-
erably better with less than 1% dying.
That nearly half of all children under five years of age
that do not receive treatment will die should be a call to
action. Mortality due to TB is likely a far more substan-
tial problem than currently thought and we urgently
need to find and treat these children to prevent un-
necessary deaths. If we assume that all of the estimated
children aged under five years with incident TB that
were not notified to the WHO in 2014 did not receive
treatment, our case fatality ratios would suggest that
173,000 of these children died. This is already
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of 136,000 and does not include children aged between
5 and 14 years old or account for any potential increased
risk associated with HIV-infection.
Tuberculosis was not mentioned in a recent paper clas-
sifying the causes of global under-five mortality [5]. As-
suming that 50% of the 136,000 deaths from TB, as per
the WHO estimate, occur in children aged under five
years, TB should have been classed as the ninth highest
cause of death worldwide in children aged 1–59 months,
above pertussis (Table in Liu et al. [5]). Our back-of-the-
envelope estimate of 173,000 children would place TB at
number six, ahead of meningitis, AIDS and measles.
The reality is that TB is causing disease in many more
young children than we realize, resulting in undiagnosed,
untreated TB and too many preventable deaths. TB is being
misdiagnosed as other diseases and is also an underlying,
undiagnosed cause of deaths that are attributed to other
more easily diagnosed diseases, including pneumonia [4].
As Graham et al. [4] pointed out, if just 10% of the 935,000
currently attributed to pneumonia [5] were in fact due to
TB, this would add a further 93,500 deaths to the WHO es-
timate of 136,000, increasing it by 69%. Full recognition of
the contribution that TB is making to under-five mortality
is a first and essential step in reducing that contribution.
Meningitis
The main cause of serious morbidity and mortality in chil-
dren with TB is TB meningitis [27]. The successes of the
roll-out of pneumococcal vaccines in recent years [45, 46]
have resulted in TB meningitis becoming one of the most
prevalent forms of bacterial meningitis [47, 48]. There are
currently no estimates of the number of children that de-
velop TB meningitis worldwide or that die from the disease,
largely due to difficulties with diagnosis [49]. However, a re-
cent study found that 19.3% (95% CI: 14.0%, 26.1%) of chil-
dren with TB meningitis will die and that among the
survivors 53.9% (95% CI: 42.6%, 64.9%) will experience
neurological sequelae [50]. Given the high mortality and
morbidity associated with this form of TB, we urgently
need to understand how many children develop and die
from this disease and where they are most prevalent. This
is a major gap in our knowledge regarding the global bur-
den of childhood TB.
Latent TB infection
One important way of preventing future morbidity and
mortality due to TB is through active case-finding to iden-
tify probable cases of latent tuberculosis infection (LTBI)
in children and target those children with preventive ther-
apy [26]. However, we need robust estimates of how many
children are likely to have LTBI and where these children
are located so that we can maximize the effectiveness of
our active case-finding. Dodd et al. estimated that 67million children under fifteen years old were infected with
TB in 2014 [21] (Table 1). The majority of these were lo-
cated in the SouthEast Asia region (27 million) and the
African region (20.9 million) [21]. In addition, Dodd et al.
estimated the number of children latently infected with
various forms of drug-resistant TB [21] (Tables 1 and 2).
These estimates by Dodd et al. were generated assuming a
constant annual rate of infection (ARI) and extrapolating
backwards over 15 years. Houben and Dodd have recently
produced an estimate of annual LTBI prevalence in chil-
dren of 97 million [51]. In their method, the historical ARI
was allowed to vary, based on changes in WHO estimates
of TB disease prevalence and direct ARI estimates from
tuberculin skin test surveys.
These are important statistics to know but it is unreal-
istic to think that all of these children can and should be
given preventive therapy. Yuen et al. recently published
estimates of how many children might be targeted for
preventive therapy [52]. The authors estimated how
many children live in a household with at least one adult
diagnosed pulmonary TB case and, therefore, have been
at risk of transmission and should be offered preventive
therapy. The authors also estimated how many of these
child contacts were likely to already have TB disease at
the time that they are investigated. The result was an
estimated 7.48 million children living with an adult diag-
nosed pulmonary TB case, of which, 2.41 million were
under five years old. Of these 7.48 million, the authors
estimated that approximately 660,000 would have TB
disease upon investigation, with 239,000 aged under five
years. National or sub-national targets such as these
allow a national tuberculosis program to plan resources
and interventions to identify and treat children at risk of
or already experiencing TB disease.
Conclusions
Focus on and development of methods to estimate the
global burden of childhood TB have advanced enor-
mously in recent years; childhood TB is starting to get
the recognition that it unfortunately deserves, although
much more could be done. Approximately 1 million
children develop TB disease each year and at least 14%
die, probably considerably more. We are beginning to
drill down and understand the burden among children
infected with HIV, as well as the risk of drug-resistant
forms of TB in children. The majority of these children
are never diagnosed with or treated for their TB disease
and TB is likely a far more important cause of under-
five mortality than is currently believed. Now that we
are beginning to appreciate the scale of the problem, we
need a more accurate understanding of precisely which
children are at greatest risk of morbidity and mortality
so that they can be targeted with preventive treatment.
No child should die from TB in the 21st century.
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